secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2023-08-29T23:59:59+00:00
Accession:  0001193125-23-222968
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FLAG shareholders approve Calidi merger; enters forward purchase & non-redemption agreements
--------------------------------------------------------------------------------

- Stockholders voted 7,039,109 for and 242,945 against the business combination with Calidi Biotherapeutics.
- Entered Forward Purchase Agreement with Meteora entities to purchase up to 340,000 shares of Class A common stock.
- Non-Redemption Agreement reverses 129,524 shares; New Calidi to pay ~$680,000 in cash upon closing.
- Series B financing from Jackson Investment Group and Calidi Cure totals $25 million; Meteora commits additional ~$1.02 million.
- Trust account estimated per-share redemption price of approximately $10.49 as of August 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/0001193125-23-222968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000119312523222968/d526016d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-222968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer